CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
SUBLICENSE REVENUE	$ 0	$ 2,000	$ 0	$ 2,000
OPERATING EXPENSES:
Sublicense transaction costs	0	254	0	254
General and administrative	178	84	366	313
Research and development	427	322	1,028	623
Total operating expenses	605	660	1,394	1,190
Income (loss) after operating expenses	(605)	1,340	(1,394)	810
Interest and other income (expense), net	(63)	(62)	(126)	(122)
Income (loss) from operations before taxes	(668)	1,278	(1,520)	688
Income tax benefit (expense)	0	0	(3)	3
NET INCOME (LOSS)	(668)	1,278	(1,523)	691
Less: Net Income (Loss) attributable to the noncontrolling interest	0	0	0	0
Net Income (Loss) attributable to Capstone Therapeutics Corp. stockholders	$ (668)	$ 1,278	$ (1,523)	$ 691
Per Share Information:
Net Income (Loss), basic and diluted, attributable to Capstone Therapeutic Corp. stockholders	$ (0.01)	$ 0.02	$ (0.03)	$ 0.01
Basic and diluted shares outstanding	54,385	54,385	54,385	54,385